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Background: Abomasal ulceration is recognized in neonatal and adult cattle, but research regarding
treatment is limited. Histamine-2 receptor antagonists (H2RA), such as famotidine, are used clini-
cally with little evidence-based research about efficacy in adult cattle.
Hypothesis and Objectives: Intravenous famotidine administered at 0.4 mg/kg will increase the
pH of abomasal outflow digesta compared to saline control in adult cattle. The objectives were to
assess the effect of famotidine, administered as a single dose and as multiple doses, on abomasal
outflow fluid pH in adult cattle. A third objective was to describe the pharmacokinetic parameters
of IV famotidine in cattle.
Animals: Four clinically healthy adult Angus-cross steers previously fitted with duodenal cannulae
placed orad to the biliary and pancreatic ducts.
Methods: Randomized, 2-way cross-over clinical trial. Steers received IV famotidine (0.4 mg/kg) as
a single and 3-dose regimen (every 8 hours) versus saline control. Blood for analysis of serum
famotidine concentration was collected intermittently for 12 hours, and abomasal outflow fluid pH
was measured at intervals for a 24-hour period. After a 34-hour washout period, the opposite
treatments were administered and the sampling repeated.
Results: Abomasal outflow fluid pH was higher in steers treated with famotidine for up to 4 hours
after a single dose but the effect decreased with subsequent doses. The median (range) elimination
half-life was 3.33 (3.21-3.54) hours.
Conclusions and Clinical Importance: Famotidine may be useful for treatment or prevention of
abomasal ulceration in adult cattle, but the duration of effect may decrease with time.
K E YWORD S
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1 | INTRODUCTION
Abomasal ulceration is a disease syndrome recognized in calves and
adult cattle. Approximately 2%-20% of both dairy and beef cattle have
abomasal ulcerations of variable severity identified at slaughter.1–3
Clinical signs of abomasal ulceration vary with severity of disease and
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include anorexia, bruxism, cranial abdominal pain, melena, signs of
localized or generalized peritonitis, anemia, and death.
In adult cattle, suggested risk factors include abomasal lymphoma,
stress from periparturient disease, diets high in carbohydrates, and use
of nonsteroidal anti-inflammatory drugs.4 Cattle admitted to veterinary
hospitals often have a combination of these risk factors, and thus are
predisposed to either having ulceration at admission or developing
ulceration during hospitalization. One of the challenges of diagnosing
and managing abomasal ulceration is the lack of sensitive and specific
definitive diagnostic tests. Presence of melena, positive fecal occult
blood tests, and typical clinical signs of bruxism and cranial abdominal
pain are suggestive of abomasal ulceration. Thus, empirical treatment
often is recommended as preventative or presumptive therapy.
Treatment of gastric ulceration in other species includes increasing
gastric pH by use of PO alkalinizing agents or suppression of gastric
acid production. The use of PO alkalinizing agents such as magnesium
hydroxide and PO gastric acid suppressants including histamine type-2
receptor antagonists (H2RA) and proton pump inhibitors (PPI) has been
studied in pre-ruminant calves.5–7 These agents have variable efficacy
in increasing abomasal pH in pre-ruminants. Administration of PO
therapies may be ineffective in adult cattle because of the buffering
and diluting effect of the rumen, unpredictable bioavailability, and
delivery to the abomasum.8 Limitations of parenteral administration of
H2RA or PPI include the need for IV access, frequent administration,
relatively large doses required, and associated cost.
Famotidine is an H2RA that competitively inhibits histamine binding
to the H2-receptor on the basolateral membrane of the parietal cells, and
thus decreases stimulation of the H1/K1 ATPase pump at the luminal
surface of the cell, which decreases acid secretion. It is used in humans
with gastric or duodenal ulceration, as well as in those with gastroesopha-
geal reflux disease.9 Dosage rates in dogs have been suggested at
0.5 mg/kg IV q12h10 and in horses at 0.2-0.4 mg/kg IV q6h-q8h.11 Evi-
dence for parental administration of gastric acid suppressants in adult cat-
tle is lacking, although anecdotal descriptions of a variety of treatments
are available.4,12 The dosage rate and frequency of administration chosen
for our study utilized the upper end of the dosage for horses (q8h) to be
able to detect an effect, if any, with a feasible time for sampling. We
hypothesized that the abomasal outflow of adult cattle receiving IV famo-
tidine will have a higher pH compared to the abomasal outflow of cattle
treated with saline control. The objectives of our study were to: (1) assess
the effect of a single dose of famotidine administered at a dosage of
0.4 mg/kg IV on the pH of abomasal outflow of adult cattle; (2) assess the
effect of famotidine administered at a dosage of 0.4 mg/kg IV on the pH
of abomasal outflow of adult cattle when administered as 3 doses q8h to
mimic clinical treatment; and (3) to describe serum concentrations and
pharmacokinetic parameters of famotidine in adult cattle.
2 | MATERIALS AND METHODS
2.1 | Animals
This study was a randomized 2-way cross-over clinical trial utilizing 4
adult Angus steers fitted previously with surgically implanted duodenal
cannulae placed orad to the biliary and pancreatic ducts. The steers
were approximately 34 months of age and weighed 800624.22 kg.
They were determined to be healthy based on clinical examination
before the study, with no previous history of ulceration. They were
housed in tie-stall stanchions for the 2 consecutive 48-hour sampling
periods. The steers were fed 2.5 kg per head of an equal mixture of
whole corn and pelleted soybean hulls twice daily at approximately
0700 and 1900 hours, starting 5 days before and during the study.
Steers also were offered ad libitum alfalfa hay and water. All animal
procedures were approved by the University of Missouri Institutional
Animal Care and Use Committee (ACUC) Protocol #8331.
2.2 | Famotidine administration
Intravenous jugular catheters (BD Angiocathm, Becton and Dickson
Therapy Systems, Inc., 9450 South State Street, Sandy, Utah) were
placed aseptically before each 48-hour study period for IV drug admin-
istration and blood sample collection. Famotidine (Famotidine Injection
USP [10 mg/mL], West-ward, Eatontown, New Jersey) was adminis-
tered at a dosage of 0.4 mg/kg IV, or an equivalent volume of saline
control, as a single dose or multiple doses as described below, and the
catheter irrigated with 10 mL of heparinized saline after administration.
The interval between the single dose and multiple dose studies was 22
hours. After a 34-hour washout period from the last treatment, the
opposite treatment was administered and the study was repeated.
Time 0 represents the time period immediately preceding administra-
tion of either famotidine or saline control, and ranged from 2 to 4
hours after feeding concentrate.
2.2.1 | Single dose study
Famotidine (0.4 mg/kg; n54) or an equivalent volume of saline (n54)
was administered via IV jugular catheter once. Blood samples from the
jugular catheter were obtained at 0, 1, 2, 3, 4, 8, 12 hours and abomasal
outflow samples were obtained hourly from 0 to 12 hours (Figure 1).
2.2.2 | Multiple dose study
Famotidine (0.4 mg/kg; n54) or an equivalent volume of saline (n54)
was administered every 8 hours at 0, 8, and 16 hours. Jugular blood
samples were obtained at 0, 8, 16, and 24 hours. Abomasal outflow
samples were obtained at 0, 1, 2, 4, 6, 8, 10, 12, 16, 17, 18, 20, 22, 24
hours (Figure 2).
2.3 | Blood sampling
Whole blood samples were obtained after 20 mL of blood and hepari-
nized saline was aspirated from the catheter to clear the catheter of
any residual drug or heparinized saline. Approximately 10 mL of whole
blood was collected into a serum separator tube containing no anticoa-
gulant (BD Vaccutainer SST Plus blood collection tubes; Becton Dick-
son and Company, Franklin Lakes, New Jersey). The 20 mL of blood
withdrawn to clear the catheter then was given back to the animal and
the catheters were irrigated with 10 mL heparinized saline. Blood sam-
ples were allowed to clot at room temperature and stored on ice for-
<8 hours before centrifugation at 1500g for 30 min at 48C. Serum
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was separated and frozen at 2208C and shipped to the laboratory for
famotidine analysis.
2.4 | Drug concentration determination and
pharmacokinetic analysis
Famotidine was quantified in bovine serum by liquid chromatography-
tandem mass spectrometry using a previously published method13 and
d-4 famotidine as the internal standard. A partial validation was per-
formed using bovine serum as the matrix. Calibration curves and nega-
tive control samples were prepared fresh for each quantitative assay
and quality control samples (bovine serum fortified with analyte at 4
concentrations within the standard curve) were included as an addi-
tional check of accuracy. The response for famotidine was linear and
gave a coefficient of determination (R2) of .99. The precision and accu-
racy of the assay were determined by assaying famotidine quality con-
trol samples in replicates (n56). The accuracy (% nominal
concentration) was 115, 104, 111, and 106% at 0.3, 25, 100, and 700
ng/mL, respectively. Precision (% relative standard deviation [SD]) was
6, 3, 5, and 2% for 0.3, 25, 100, and 700 ng/mL, respectively. The assay
was optimized to provide a limit of quantitation of 0.2 ng/mL and a
limit of detection of approximately 0.1 ng/mL. To assess the potential
impact of the silicone plug in the serum separator tubes on famotidine
concentrations (ie, drug binding), control bovine serum was collected
into both serum separator tubes and serum tubes without the silicone
plug. Famotidine, at 1 of 3 concentrations (1 ng/mL, 5 ng/mL, and 10
ng/mL), was added to serum in the different tube types. Each concen-
tration was spiked in triplicate. Tubes containing drug were allowed to
sit at room temperature for 1 hour. Drug concentrations in each tube
were measured as described above for the in vivo samples.
Pharmacokinetic analysis was performed on serum famotidine con-
centrations using non-compartmental analysis and a commercially avail-
able software program (Phoenix WinNonlin Version 6.2; Pharsight,
Cary, North Carolina). The sampling time points in this study were
more fitting for non-compartmental versus compartmental methods to
determine pharmacokinetic parameters. The elimination rate constant
(lambdaz) was calculated by determination of the slope of the terminal
portion of the plasma concentration versus time curve and the plasma
elimination half-life (HL) using the formula (ln 2)/the elimination rate
constant. The area under the curve (AUC) from 0 to infinity (0-1) was
calculated using the log-linear trapezoidal method. The AUC0-1 %
extrapolated was calculated using the formula [(AUC0-12AUC0–12)/
AUC0-1] 3 100.
2.5 | Abomasal outflow fluid sampling and pH
measurement
Abomasal outflow fluid sampled from the duodenal cannulae was used
as an indicator of abomasal pH changes due to orad placement from
biliary and pancreatic ducts. Approximately 50 mL of duodenal fluid
was allowed to drain from the cannula before collecting 20 mL in to a
plastic collection bag (Whirl-Pak bags; Nasco, Modesto, California) by
gravity flow. The operator obtaining the samples and measuring pH
was not blinded to the treatment or sample time.
Abomasal outflow pH was analyzed directly after sampling (within
5 minutes) using a bench-top pH analyzer (Fisher Science Accumet;
Thermo Fisher Scientific, Inc, Blk 55 Ayer Rajah Crescent, Singapore).
FIGURE 1 Schematic of the single dose study: a single dose of intravenous famotidine (0.4 mg/kg) (n52) or an equivalent volume of
saline (n52) administered at 0 hours. Blood samples were obtained at 0, 1, 2, 3, 4, 8, 12 hours. Abomasal outflow fluid samples were
obtained hourly at 0–12 hours
FIGURE 2 Schematic of the multi-dose study: Three doses of intravenous famotidine (0.4 mg/kg) (n52) or an equivalent volume of saline
(n52) administered at 0, 8, and 16 hours. Blood samples were obtained at 0, 8, 16, and 24 hours. Abomasal outflow fluid samples were
obtained at 0, 2, 4, 6, 8, 10, 12, 14, 16, 17, 18, 20, and 24 hours
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The pH meter was calibrated according to manufacturer’s instructions
with 4.01 and 7.0 pH solutions at the start of the study and once every
12 hours. Outflow samples that appeared grossly contaminated with
bile, flowed very slowly, or had a pH>5.0 were resampled within a
10-minute period. If the second sample had a pH measurement within
0.25 units of the initial reading, the original sample value was recorded.
If the second sample had a pH that was>0.25 units more acidic than
the initial sample, the new sample pH value was recorded. Any samples
that had a pH>5.0, or had gross contamination with bile or mucus
were recorded, but not included in data analysis because they were
considered an inaccurate reflection of abomasal outflow pH.
2.6 | Abomasal outflow pH statistical analysis
For abomasal outflow pH, a mixed model analysis with commercial
software (SAS Version 9.4; SAS Institute Inc, Cary, North Carolina) was
used. The MIXED procedure was used with treatment, sampling hour,
and treatment 3 hour as the fixed effects and steer and period as ran-
dom effects in the model. Least square means were separated using
least significant difference and analyzed using analysis of variance.
P< .05 was considered statistically significant.
3 | RESULTS
The treatment 3 sampling hour interaction affected abomasal outflow
pH for both a single dose and multiple doses of famotidine (P< .001).
A single dose of famotidine at 0.4 mg/kg significantly increased the pH
of abomasal outflow fluid for 4 hours (P < .05) compared with saline
control (Figure 3). The greatest difference was observed at 2 hours
post-treatment with least square (LS) means6 SD pH values 3.906
0.12 (control) versus 6.0160.18 (famotidine; P< .001). When adminis-
tered every 8 hours, famotidine significantly increased the pH of abo-
masal outflow fluid for 3 hours after the first dose, 2 hours after the
second dose, and only 1 hour after the third dose (Figure 4). The great-
est difference was observed 2 hours after the first treatment with LS
means6 SD pH values of 4.4960.30 (control) versus 5.6760.27
(famotidine; P< .001). The pH of outflow in the control group was less
at 9 hours than at hours 1, 4, and 12 (P .04). Otherwise, the outflow
pH of the control group did not change over time (P> .10).
Serum famotidine concentrations with respect to time after a sin-
gle administration are summarized in Table 1 and shown in Figure 5.
Measured serum famotidine concentrations from spiked serum separa-
tor tubes were 93%-95% of the concentrations measured in serum
tubes without the silicone plug at all concentrations studied.
Pharmacokinetic parameters after administration of a single dose of
famotidine are summarized in Table 2. The median (range) HL (Lambdaz),
volume of distribution (Vdss), and clearance (CL) were 3.33 (3.21-3.54)
hours, 0.042 (0.014-1.89) L/kg, and 1.26 (0.625-11.5) mL/min/kg,
respectively. Serum concentrations with respect to time after multiple
doses are depicted in Table 3. Pharmacokinetic analysis was not per-
formed on the multiple dose data because of a limited number of time
points and a small number of animals (n52 for time 8 and 16 hours and
n54 for time 0 and 24 hours).
No adverse clinical effects were observed in the steers for the
duration of study period, based on lack of clinical abnormalities such as
changes in fecal consistency, appetite, attitude, and physical examina-
tion findings at the conclusion of the study.
FIGURE 3 Least square means and standard deviation pH of
abomasal outflow fluid from adult cattle (n54) administered a
single intravenous dose of 0.4 mg/kg famotidine (circles) compared
with adult cattle (n54) administered an equivalent volume of
saline (squares). *Denotes statistical significance (P< .05)
FIGURE 4 Least square means and standard deviation pH of
abomasal outflow fluid from adult cattle (n54) administered
multiple intravenous doses of 0.4 mg/kg famotidine (circles) every
8 hours (time 0, 8, 16 hours) compared with adult cattle (n54)
administered an equivalent volume of saline (squares). *Denotes
statistical significance (P< .05)
TABLE 1 Serum concentration of famotidine when administered as a single dose of 0.4 mg/kg IV at 0 hour to adult cattle (n54)
Serum concentration (ng/mL)
Time (hour)
0 1 2 3 4 8 12
Median NDa 821.8 43.5 30.4 17.9 9.2 4.1
Range (ng/mL) NDa (154.9–1232) (35.1–50.9) (26.4–35.6) (13.1–22.0) (5.2–12.1) (2.8-6.2)
aLimit of detection of approximately 0.1 ng/mL.
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4 | DISCUSSION
To our knowledge, this study is the first investigation of parenteral
administration of famotidine in adult cattle. Our results indicate that
famotidine administered at a dosage of 0.4 mg/kg IV is effective at
increasing the abomasal outflow fluid pH of adult cattle for up to 4
hours after a single dose compared with saline control. When adminis-
tered every 8 hours, as is typically done for clinical treatment,11 famoti-
dine increased the pH of the abomasal outflow fluid, but the effect
decreased with additional doses. Famotidine increased the abomasal
outflow fluid pH for 3 hours after the first dose, 2 hours after the sec-
ond dose, and for only 1 hour after the third dose. This phenomenon
of tachyphylaxis has been described in humans and a decrease in
response to treatment with H2RA has been reported after the second
dose and with repeated PO dosing of famotidine in dogs.14,15 How-
ever, although the effect on acid secretion was reported to be negligi-
ble in these studies of humans, there was a perceived effect of
treatment, which may be a result of other mechanisms. In humans,
plasma concentration is dose-related with greater acid suppression cor-
related with larger doses.16 Similar studies have not been performed in
veterinary species to our knowledge. The mechanisms of a decreasing
effect on acid secretion in cattle are not known, and may occur through
a similar process, such as degradation of parietal cell H2-receptors with
time.17 The presence of tachyphylaxis is clinically important when rec-
ommending dosing interval or frequency.15
Previous reports describing use of other H2RA in ruminants have
been published. In 1 report, abomasal pH increased for 1 hour after
administration of ranitidine (6.6 mg/kg IM) in cattle.12 Other studies
have reported a dose-dependent effect of PO cimetidine and ranitidine
in pre-ruminant calves.5 The effect of IV ranitidine has been investi-
gated in sheep with abomasal cannulae, indicating that a dosing interval
of every 8–12 hours is most effective.18 That study, however, also
found that sheep receiving ranitidine had increased total serum protein
and increased serum creatinine concentrations, increased aspartate
aminotransferase activity, and decreased serum pepsinogen concentra-
tion, indicating safety concerns for this agent in sheep.18
Drugs that increase gastric pH above 3.0 for up to 75% of a 24-
hour period may be associated with healing of gastric or duodenal
ulcers in humans.19 When administered as a single dose, famotidine
significantly increased the abomasal outflow pH compared to the con-
trols for up to 4 hours, from a baseline of 4.2660.81 pretreatment to
a high of 6.0160.18 at 2 hours post-administration of famotidine.
When administered every 8 hours, as has been clinically recommended,
the greatest difference between control- and famotidine-treated cattle
occurred 2 hours after administration of the first dose. However, the 2
groups were only different for 7 hours of a 24-hour period, which
equates to approximately 30% of the day. This is less than the
observed 48.9% of a 24-hour period in dogs treated with famotidine
(0.5 mg/kg IV q12h)10 and less than the 75% of the day recommended
in humans.19 This finding suggests that administering H2RA every 8
hours may not be cost-effective if there is no clinical effect, and per-
haps may have the same duration of effect in a 24-hour period, if
administered less frequently. These percentages are less than the sug-
gested interval for treatment of humans, but the optimal degree of gas-
tric acid suppression has not been clearly defined in veterinary species,
including cattle.
Our study reports higher pH values obtained for fluid from duode-
nal cannulae as compared with studies with direct luminal abomasal
fluid measurement in calves and adult cattle, either from direct cannu-
lation or abomasocentesis,5,7,8,20,21 which may be a consequence of
backflow of biliary and pancreatic secretions and mucus production by
FIGURE 5 Semi-log plot of serum concentrations of famotidine
after administration of a single intravenous dose of famotidine
(0.4 mg/kg) to adult cattle (n54). Data presented as mean6
standard deviation
TABLE 2 Median (range) pharmacokinetic parameters after admin-
istration of a single IV dose of famotidine (0.4 mg/kg) to adult cat-
tle (n54)
Parameters Median (range)
Lambdaz (1/h) 0.208 (0.196-0.216)
HL Lambdaz (h) 3.33 (3.21-3.54)
Vdss (L/kg) 0.042 (0.014-1.89)
CL (mL/min/kg) 1.26 (0.625-11.5)
AUC (h 3 ng/mL) 7,019 (579-10 673)
AUC extrap (%) 0.326 (0.129-5.46)
AUC, area under the curve; CL, clearance; HL, half-life; Vdss, volume of
distribution.
TABLE 3 Serum concentration of famotidine when administered as
3 doses of 0.4 mg/kg IV at 0, 8, and 16 hours to adult cattle (n54)
Serum concentration (ng/mL)
Time (hour)
0 8 16 24
Median NDa 935.5b 4217.4b 761.8
Range
(ng/mL)
NDa (411.3–1459.7)b (453.4–7981.3)b (100.2–5858.5)
aLimit of detection of approximately 0.1 ng/mL.
bn52.
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small intestinal enterocytes. Correct placement of the duodenal cannu-
lae was determined at the time of surgical implantation by measure-
ment of pH, and thus was unlikely to have caused the difference in our
study, especially based on consistency among individuals. Additionally,
minimal fluctuation was observed in the abomasal outflow pH of con-
trol steers during the study period, suggesting that feeding concentrate
did not have an effect on the acid secretion and pH of the abomasal
outflow fluid in our study.
In our study, the HL of famotidine was just over 3 hours, suggest-
ing that>99% of the drug would be eliminated within 24 hours (7
elimination HL) post-administration. However, only serum was
obtained in this study and a multi-dose regimen with tissue samples
would be required to determine accurate tissue residues to determine
appropriate withdrawal times. Veterinarians are recommended to con-
sult the Food Animal Residue Avoidance Database (FARAD), or other
regulatory body, for recommendations on withdrawal times after
administration of this medication, because famotidine currently is not
approved for use in food-producing animals in the United States and
its use is considered extra-label.
Limitations of our study include small sample size, short study
period, and use of a single IV catheter for administration and sampling.
A small sample size may increase the effect of individual variation,
especially when interpreting the pharmacokinetic data. The short 34-
hour washout period between studies may have allowed an unknown
residual effect of the drug on the parietal cells within the abomasum.
To more accurately analyze the pharmacokinetic indices of famotidine,
more frequent blood sampling would have been necessary directly
after administration of the drug, but due to certain constraints, this was
not possible for our study. The Cmax, in particular, would be affected, as
the lack of initial data points may have resulted in the failure to identify
the true peak concentration, which may have occurred before the first
data point. More data points would have changed the shape of the
time-concentration curve, and thus the AUC and CL values are likely to
have been underestimated, because of the first data point being an
hour after administration.
Because of personnel limitations and temperament of the cattle,
direct IV administration of the treatment was not practical for this pilot
study. Utilizing the same IV catheter for administration of drug and
blood sample collection may have altered the measured serum famoti-
dine concentrations because of crystallization of famotidine within the
catheter or extension set. Additionally, returning the 20 mL of blood
taken before sample collection to the animal post-sampling may have
inadvertently readministered drug remaining within the catheter, also
affecting the pharmacokinetic analysis. In particular, 1 steer in the
multi-dose section of the study had repeatedly higher serum famoti-
dine concentrations than the others steers, which may have been
caused by individual variation, but the possibility of sampling error as a
result of the above-mentioned issues cannot be ruled out. In addition,
some data points for the multi-dose study were not available, thus
making interpretation of the pharmacokinetic analysis of the multi-
dose study problematic.
More frequent abomasal outflow fluid samples or continuous sam-
pling by pH electrode through the cannulae would have allowed
detection of the initial effects of famotidine on parietal cell secretion
and a more accurate detection of the timing of abomasal outflow pH
changes. Studies with larger numbers of individuals using direct abo-
masal cannulation 5,7,20 or using repeated percutaneous ultrasound-
guided abomasocentesis21 may have resulted in more accurate meas-
urements of abomasal pH.
This pilot study facilitates further studies assessing different dosage
rates and dosing intervals of famotidine, as well as investigating the
effect of different commercially available gastric acid suppressant thera-
peutic drugs in cattle and other ruminant species. Further studies inves-
tigating the efficacy of famotidine after extravascular administration
may be clinically useful. In conclusion, famotidine when administered
parenterally at a dosage of 0.4 mg/kg is effective at increasing abomasal
outflow pH for at least 4 hours after a single dose, and could be a useful
adjunctive treatment for abomasal ulceration in adult cattle, but should
not be the sole form of treatment. Further studies are needed to evalu-
ate the use of this drug, especially dose rates and frequency.
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